Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Restructuring Costs (2024 - 2025)

aTYR PHARMA's Restructuring Costs history spans 2 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Restructuring Costs fell 2.6% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $13.7 million, up 20.43%, while the annual FY2025 figure was $13.7 million, 20.42% up from the prior year.
  • Restructuring Costs reached $2.8 million in Q4 2025 per ATYR's latest filing, down from $3.9 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $3.9 million in Q2 2025 to a low of $2.8 million in Q2 2024.